GDC-2394 是一种口服有效、选择性的
NLRP3抑制剂,同时也抑制
IL-1β,
IC50为 0.4 μM (human IL-1β) 和 0.1 μM (mouse IL-1β)。GDC-2394 抑制 NLRP3 诱导的
caspase-1活性,但不抑制 NLRC4 依赖的炎症小体激活。
生物活性 |
GDC-2394 is an orally active and selectiveNLRP3inhibitor, and also inhibitsIL-1βwithIC50s of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β). GDC-2394 inhibits NLRP3-inducedcaspase-1activity without inhibiting NLRC4-dependent inflammasome activation[1][2].
|
体外研究 (In Vitro) |
GDC-2394 (20 μM; 30 min) inhibits NLRP3-induced apoptosis associated speck-like protein containing CARD (ASC) speck formation in THP-1 cells[1]. GDC-2394 (1 nM-10 μM; 7 d) inhibits human macrophage IL-1β and IL-18 production after activation of the NLRP3 inflammasome[1]. GDC-2394 (0-20 μM; 30 min) inhibits NLRP3-dependent caspase-1 activation (IC50=51 nM) in THP-1 cells, also inhibits NLRP3-dependent IL-1β release (IC50=63 nM) and NLRC4-dependent IL-1β release (IC50>20 μM) in mouse bone marrow-derived macrophages (mBMDMs)[1].
|
体内研究 (In Vivo) |
GDC-2394 (compound 20) (1 mg/kg, 10 mg/kg; p.o.; single dose) inhibits production of IL-1β in an acute mouse peritonitis model[1]. GDC-2394 (25 mg/kg; once daily for 7 d) reduces paw swelling and pain in a functional rat model of gouty arthritis[1].
Preclinical PK of GDC-2394[1].
Species |
Mouse |
Rat |
Dog |
Cyno |
CLp(mL/min/kg) |
10.1 |
1.3 |
11.7 |
4.1 |
Vss(L/kg) |
0.72 |
0.29 |
0.67 |
0.18 |
T1/2(h) |
1.2 |
4.4 |
0.99 |
0.89 |
%F (1 mg/kg) |
80 |
33 |
78 |
53 |
Animal Model: |
Acute mouse peritonitis model[1] |
Dosage: |
1 mg/kg and 10 mg/kg |
Administration: |
Oral gavage; 2 h later treated with 1.25 μg LPS (i.p.) followed by 1 mg monosodium urate crystals (i.p.) a further 2 h later. |
Result: |
Resulted in a dose-dependent decrease in peritoneal IL-1β concentrations after MSU treatment, and decreased the level of IL-1β by 66.8 and 81.3% at 1 and 10 mg/kg compared with the control. |
Animal Model: |
Functional rat model of gouty arthritis[1] |
Dosage: |
25 mg/kg |
Administration: |
Interventional injection; once daily for 7 days |
Result: |
Significantly inhibited knee swelling after 48 h. |
|
分子量 |
|
性状 |
|
Formula |
|
CAS 号 |
|
运输条件 |
Room temperature in continental US; may vary elsewhere.
|
储存方式 |
Powder |
-20°C |
3 years |
In solvent |
-80°C |
6 months |
|
-20°C |
1 month |
|
溶解性数据 |
In Vitro:
DMSO : 125 mg/mL(289.68 mM;Need ultrasonic)
配制储备液
1 mM |
2.3174 mL |
11.5872 mL |
23.1744 mL |
5 mM |
0.4635 mL |
2.3174 mL |
4.6349 mL |
10 mM |
0.2317 mL |
1.1587 mL |
2.3174 mL |
*
请根据半岛bd体育手机客户端 在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的半岛bd体育手机客户端 失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。
In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
-
1.
请依序添加每种溶剂: 10% DMSO40%PEG3005%Tween-8045% saline
Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.82 mM,饱和度未知) 的澄清溶液。
以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。
-
2.
请依序添加每种溶剂: 10% DMSO90% (20%SBE-β-CDin saline)
Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.82 mM,饱和度未知) 的澄清溶液。
以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。
-
3.
请依序添加每种溶剂: 10% DMSO90%corn oil
Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.82 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。
*
以上所有助溶剂都可在本网站选购。
|